Regeneron Pharmaceuticals reported trailing twelve-month Free Cash Flow (FCF) of $3.4 billion. Looking ahead, analysts project significant growth, forecasting FCF to rise to around $8 billion by 2035. Based on these projections and using a two-stage model to capture both near-term growth and a longer steady-state, Regeneron's intrinsic value is estimated at $1,544 per share.